FANCONI ANEMIA (FA) is a rare autosomal recessive disorder characterized by short stature, various congenital malformations, progressive bone marrow failure at an early age, and cancer development.
1,2 Fanconi anemia is characteristically defined by its cellular hypersensitivity to DNA cross-linking agents such as diepoxybutane and mitomycin.
3 Based on the presence of mutations in one of the FA genes, FA can be divided into 8 complementation groups (A-G, including D1 and D2), with each group having in common the cellular hypersensitivity to cross-linking agents.
4,5 Complementation groups A (65%), C (15%), and G (10%) account for most patients with this disorder reported to the International Fanconi Anemia Registry (IFAR). The severity of the phenotype is determined in part by the specific complementation group and more significantly by the type of genetic mutation.
6 Because of these phenotypic differences among complementation groups, FA is a heterogeneous disorder; patients may be severely affected, with multiple congenital anomalies and severe aplastic anemia, or may have a mild phenotype, with no major malformations or hematologic abnormalities.
7